Two new novel treatments show promise for migraine treatment, according to two studies that will be presented at the annual meeting of the American Academy of Neurology, held from April 26-May 3 in Philadelphia. A genetically engineered humanized anti-calcitonin gene-related peptide (CGRP) antibody, ALD403, and a fully humanized monoclonal antibody to CGRP, LY2951742 have been shown to help assist in migraine treatment.
Peter Goadsby, MD, PhD, from the University of San Francisco, and colleagues examined the effectiveness and safety of a ALD403 for migraine prevention. A total of 163 with 5-14 days of migraines per month were randomized to receive a single dose of ALD403 or the placebo. 81 patients received ALD403 while 82 received the placebo. From baseline to weeks 5-8, the researchers discovered a 66% decrease in migraine days per week for ALD403 and a 52% decrease for placebo (-5.6 vs. -4.6; one-sided P=0.03).
David Dodick, MD, from the Mayo Clinic in Arizona in Phoenix, and colleagues enrolled patients with 4-14 migraine days per month into a randomized controlled trial of biweekly subcutaneous injections of 150mg LY2951742, which 107 patients received, vs. a placebo, which 110 patients received. The researchers discovered that compared with baseline, the mean change in migraine headache days per month at 12 weeks was -4.2 (62.5% decrease) for LY2951742, compared with -3.0 (42.3% decrease) for the placebo (P<0.003). For all secondary end points, LY2951742 was better than the placebo.
“We’re cautiously optimistic that a new era of mechanism-based migraine prevention is beginning,” Dodick said in a statement.
Goadsby’s study was supported by Alder Biopharmaceuticals while Dodick’s study was supported by Arteus.
When these two studies are presented at the annual meeting of American Academy of Neurology later this week, it is possible that the two novel treatments may be approved to find their way into the medicine cabinets of U.S. households to aid with migraine treatment.